Target Name: DDA1
NCBI ID: G79016
Other Name(s): PCIA1 | PCIA-1 | C19orf58 | DET1- and DDB1-associated protein 1 | Placenta cross-immune reaction antigen 1 | DET1 and DDB1 associated 1 | placenta cross-immune reaction antigen 1 | DDA1_HUMAN | cross-immune reaction antigen PCIA1 | Cross-immune reaction antigen PCIA1

PCIA1 as A Drug Target and Biomarker for Diseases

Drug discovery is an ongoing process that involves the identification and development of potential therapeutic compounds. One of the promising strategies in drug discovery is the use of protein biomarkers, which are derived from proteins that are expressed and can be measured in the body. One of the protein biomarkers that has gained significant attention in recent years is PCIA1 (Peroxisome proliferator-activated receptor-like protein-1), which is a G protein-coupled receptor (GPCR) that is involved in various physiological processes in the body.

In this article, we will discuss PCIA1 as a drug target and its potential as a biomarker for various diseases.

Drug Target: PCIA1

PCIA1 is a GPCR that is expressed in various tissues in the body, including the brain, heart, and pancreas. It is involved in the regulation of various physiological processes, including inflammation, stress, and metabolism. The primary function of PCIA1 is to regulate the production of pro-inflammatory cytokines, which play a crucial role in the development of various diseases, including cancer, cardiovascular disease, and neurodegenerative diseases.

One of the unique features of PCIA1 is its ability to interact with multiple GPCRs, which allows it to regulate a wide range of physiological processes. This makes it an attractive drug target for researchers because it has the potential to modulate a broad range of cellular processes that are associated with various diseases.

Targeting PCIA1

Drug discovery efforts have focused on developing small molecules that can inhibit PCIA1 function and reduce the production of pro-inflammatory cytokines. These small molecules have been shown to have a wide range of effects, including reducing inflammation, improving insulin sensitivity, and modulating the expression of other genes.

One of the most promising small molecules that has been shown to interact with PCIA1 is called U4112, which is a potent inhibitor of PCIA1. U4112 has been shown to reduce the production of pro-inflammatory cytokines in various cell types, including cancer cells and immune cells.

Another small molecule that has been shown to interact with PCIA1 is called DPP (1-[3-(4-methoxybenzamid)-4-carboxypropanamid), which is a potent modulator of PCIA1 function. DPP has been shown to increase the amount of PCIA1 in the brain, which may have implications for the treatment of various neurological disorders.

Biomarker Potential

PCIA1 has the potential to serve as a biomarker for various diseases, including cancer, cardiovascular disease, and neurodegenerative diseases. The production of pro-inflammatory cytokines is a key indicator of inflammation in the body, and PCIA1 plays a critical role in regulating the production of these cytokines. Therefore, measuring the levels of PCIA1 in the body may be a useful biomarker for various diseases.

One of the promising applications of PCIA1 as a biomarker is its potential to monitor the effectiveness of anti-inflammatory therapies. For example, researchers have used PCIA1 levels as a marker to assess the effectiveness of various anti-inflammatory treatments, including nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.

Another application of PCIA1 as a biomarker is its potential to monitor the progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the production of pro-inflammatory cytokines. Therefore, measuring the levels of PCIA1 in the brain may be a useful biomarker for the diagnosis and treatment of these conditions.

Conclusion

In conclusion, PCIA1 is a promising drug target and biomarker for various diseases. Its unique ability to interact with multiple GPCRs and its potential as a regulator of pro-inflammatory cytokines make it an attractive target for drug discovery. Further research is needed to

Protein Name: DET1 And DDB1 Associated 1

Functions: Functions as a component of numerous distinct DCX (DDB1-CUL4-X-box) E3 ubiquitin-protein ligase complexes which mediate the ubiquitination and subsequent proteasomal degradation of target proteins (PubMed:17452440, PubMed:28437394, PubMed:28302793, PubMed:31686031, PubMed:31819272). In the DCX complexes, acts as a scaffolding subunit required to stabilize the complex (PubMed:31686031, PubMed:31819272)

More Common Targets

DDAH1 | DDAH2 | DDB1 | DDB2 | DDC | DDC-AS1 | DDD core complex | DDHD1 | DDHD2 | DDI1 | DDI2 | DDIAS | DDIT3 | DDIT4 | DDIT4L | DDN | DDO | DDOST | DDR1 | DDR2 | DDRGK1 | DDT | DDTL | DDX1 | DDX10 | DDX11 | DDX11-AS1 | DDX11L1 | DDX11L10 | DDX11L2 | DDX11L8 | DDX11L9 | DDX12P | DDX17 | DDX18 | DDX18P1 | DDX19A | DDX19A-DT | DDX19B | DDX20 | DDX21 | DDX23 | DDX24 | DDX25 | DDX27 | DDX28 | DDX31 | DDX39A | DDX39B | DDX39B-AS1 | DDX3P1 | DDX3X | DDX3Y | DDX4 | DDX41 | DDX42 | DDX43 | DDX46 | DDX47 | DDX49 | DDX5 | DDX50 | DDX50P1 | DDX51 | DDX52 | DDX53 | DDX54 | DDX55 | DDX56 | DDX59 | DDX59-AS1 | DDX6 | DDX60 | DDX60L | DDX6P1 | DEAF1 | Death-associated protein kinase | Decapping Complex | DECR1 | DECR2 | DEDD | DEDD2 | Dedicator of cytokinesis protein | DEF6 | DEF8 | DEFA1 | DEFA10P | DEFA11P | DEFA1B | DEFA3 | DEFA4 | DEFA5 | DEFA6 | DEFA7P | DEFA8P | DEFA9P | DEFB1 | DEFB103A | DEFB103B | DEFB104A